AO
CRSP icon

Advisor OS’s CRISPR Therapeutics CRSP Stock Holding History

Advisor OS’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$504K Sell
9,249
-258
-3% -$13.6K 0.03% 314
2026
Q1 		$452K Buy
+9,507
New +$501K 0.03% 320
2024
Q2 		– Sell
-3,117
Closed -$212K – 394
2024
Q1 		$212K Sell
3,117
-330
-10% -$23.6K 0.02% 366
2023
Q4 		$216K Buy
+3,447
New +$191K 0.03% 312
2021
Q4 		– Sell
-2,012
Closed -$225K – 243
2021
Q3 		$225K Hold
2,012
– – 0.05% 213
2021
Q2 		$326K Hold
2,012
– – 0.07% 183
2021
Q1 		$245K Buy
2,012
+2
+0.1% +$302 0.06% 177
2020
Q4 		$308K Buy
+2,010
New +$238K 0.08% 105

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Advisor OS's CRSP Position: Q2 2026 in Review

Advisor OS reduced its CRISPR Therapeutics (CRSP) stake by 2.7% in Q2 2026, selling an estimated $13.6K and leaving 9,249 shares worth $504K. The position accounts for 0.03% of the portfolio, ranked #314.

Advisor OS first reported a position in CRSP in Q4 2020 and has held it in 8 quarters since. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Advisor OS held 9,249 shares of CRISPR Therapeutics worth $504K as of Q2 2026.
  • Advisor OS sold 258 CRISPR Therapeutics shares in Q2 2026, an estimated $13.6K.
  • CRISPR Therapeutics made up 0.03% of Advisor OS's portfolio in Q2 2026, its #314 holding.
  • Advisor OS first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 8 quarters since.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Advisor OS's 13F filing for Q2 2026, filed 5 Aug 2026.